AI Summary
We reviewed 6 live results for stelara (ustekinumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Biosimilars.
Comparison Table
Recommended
Stelara (ustekinumab)
Source: Janssen
Description
Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion.
Best for
pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management
View Details
Rating
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
Epyztek (ustekinumab)
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
patients in South Korea, psoriasis treatment and local biosimilar seekers
View Details
Rating
| Compare | Stelara (ustekinumab) | Steqeyma (ustekinumab biosimilar) | Epyztek (ustekinumab) |
|---|---|---|---|
| Source | Janssen | Celltrion Healthcare | Samsung Bioepis |
| Description | Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion. | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. |
| Best for | pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users | patients in South Korea, psoriasis treatment and local biosimilar seekers |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Stelara (ustekinumab) from Janssen."
I picked this because As the originator product with extensive clinical history and current HSA registration, Stelara is the standard of care for ustekinumab therapy in Singapore.
Share this search
Related Finds